Peyrin-Biroulet L - Search Results

1

Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases.

Colombel JF, Narula N, Peyrin-Biroulet L. Colombel JF, et al. Gastroenterology. 2017 Feb;152(2):351-361.e5. doi: 10.1053/j.gastro.2016.09.046. Epub 2016 Oct 5. Gastroenterology. 2017. PMID: 27720840 Review.

2

PPARgamma as a new therapeutic target in inflammatory bowel diseases.

Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P. Dubuquoy L, et al. Gut. 2006 Sep;55(9):1341-9. doi: 10.1136/gut.2006.093484. Gut. 2006. PMID: 16905700 Free PMC article. Review.

3

Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine.

Peyrin-Biroulet L, Rodriguez-Guéant RM, Chamaillard M, Desreumaux P, Xia B, Bronowicki JP, Bigard MA, Guéant JL. Peyrin-Biroulet L, et al. Am J Gastroenterol. 2007 May;102(5):1108-15. doi: 10.1111/j.1572-0241.2007.01170.x. Epub 2007 Mar 13. Am J Gastroenterol. 2007. PMID: 17355415 Review.

4

Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.

Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Peyrin-Biroulet L, et al. World J Gastroenterol. 2007 Apr 28;13(16):2328-32. doi: 10.3748/wjg.v13.i16.2328. World J Gastroenterol. 2007. PMID: 17511032 Free PMC article. Clinical Trial.

5

[Helminths and inflammatory bowel diseases].

Laclotte C, Oussalah A, Rey P, Bensenane M, Pluvinage N, Chevaux JB, Trouilloud I, Serre AA, Boucekkine T, Bigard MA, Peyrin-Biroulet L. Laclotte C, et al. Gastroenterol Clin Biol. 2008 Dec;32(12):1064-74. doi: 10.1016/j.gcb.2008.04.030. Epub 2008 Jul 10. Gastroenterol Clin Biol. 2008. PMID: 18619749 French.

6

Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience.

Oussalah A, Babouri A, Chevaux JB, Stancu L, Trouilloud I, Bensenane M, Boucekkine T, Bigard MA, Peyrin-Biroulet L. Oussalah A, et al. Aliment Pharmacol Ther. 2009 Feb 15;29(4):416-23. doi: 10.1111/j.1365-2036.2008.03902.x. Epub 2008 Nov 25. Aliment Pharmacol Ther. 2009. PMID: 19035976

7

A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.

Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B. Roblin X, et al. Am J Gastroenterol. 2008 Dec;103(12):3115-22. doi: 10.1111/j.1572-0241.2008.01743.x. Am J Gastroenterol. 2008. PMID: 19086961 Retracted. Clinical Trial.

8

Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health.

Peyrin-Biroulet L, Cieza A, Sandborn WJ, Kostanjsek N, Kamm MA, Hibi T, Lémann M, Stucki G, Colombel JF. Peyrin-Biroulet L, et al. Inflamm Bowel Dis. 2010 Jan;16(1):15-22. doi: 10.1002/ibd.21010. Inflamm Bowel Dis. 2010. PMID: 19610077

9

Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.

Oussalah A, Roblin X, Laharie D, Filippi J, Flamant M, Faure P, Phelip JM, Bigard MA, Peyrin-Biroulet L. Oussalah A, et al. Aliment Pharmacol Ther. 2009 Oct 15;30(8):854-63. doi: 10.1111/j.1365-2036.2009.04097.x. Aliment Pharmacol Ther. 2009. PMID: 19764940

10

Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France.

Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L. Chevaux JB, et al. Inflamm Bowel Dis. 2010 Jun;16(6):916-24. doi: 10.1002/ibd.21147. Inflamm Bowel Dis. 2010. PMID: 19885908

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results